JP2008517915A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008517915A5 JP2008517915A5 JP2007538016A JP2007538016A JP2008517915A5 JP 2008517915 A5 JP2008517915 A5 JP 2008517915A5 JP 2007538016 A JP2007538016 A JP 2007538016A JP 2007538016 A JP2007538016 A JP 2007538016A JP 2008517915 A5 JP2008517915 A5 JP 2008517915A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- group
- alkoxy
- pharmaceutical composition
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003545 alkoxy group Chemical group 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 208000006673 asthma Diseases 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 201000004624 Dermatitis Diseases 0.000 claims 6
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 6
- 210000000056 organ Anatomy 0.000 claims 5
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 206010046851 Uveitis Diseases 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 208000023589 ischemic disease Diseases 0.000 claims 4
- 238000002054 transplantation Methods 0.000 claims 4
- 201000004384 Alopecia Diseases 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims 3
- 206010034277 Pemphigoid Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 206010040047 Sepsis Diseases 0.000 claims 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 3
- 125000004423 acyloxy group Chemical group 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 230000008938 immune dysregulation Effects 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 208000023504 respiratory system disease Diseases 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 201000000306 sarcoidosis Diseases 0.000 claims 3
- 230000035939 shock Effects 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000028185 Angioedema Diseases 0.000 claims 2
- 206010002660 Anoxia Diseases 0.000 claims 2
- 241000976983 Anoxia Species 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000009137 Behcet syndrome Diseases 0.000 claims 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 206010048962 Brain oedema Diseases 0.000 claims 2
- 206010009657 Clostridium difficile colitis Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims 2
- 206010012335 Dependence Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 206010019663 Hepatic failure Diseases 0.000 claims 2
- 206010019799 Hepatitis viral Diseases 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- GWNVDXQDILPJIG-SHSCPDMUSA-N Leukotriene C4 Natural products CCCCCC=C/CC=C/C=C/C=C/C(SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)C(O)CCCC(=O)O GWNVDXQDILPJIG-SHSCPDMUSA-N 0.000 claims 2
- 206010051606 Necrotising colitis Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010029240 Neuritis Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 206010036105 Polyneuropathy Diseases 0.000 claims 2
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 claims 2
- 206010037128 Pseudomembranous colitis Diseases 0.000 claims 2
- 208000033626 Renal failure acute Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 206010039966 Senile dementia Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 208000024248 Vascular System injury Diseases 0.000 claims 2
- 208000012339 Vascular injury Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 201000011040 acute kidney failure Diseases 0.000 claims 2
- 208000012998 acute renal failure Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 230000007953 anoxia Effects 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 208000006752 brain edema Diseases 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 2
- -1 each optionally -F Chemical group 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 230000003779 hair growth Effects 0.000 claims 2
- 229960001340 histamine Drugs 0.000 claims 2
- 206010021198 ichthyosis Diseases 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 208000023569 ischemic bowel disease Diseases 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 206010023332 keratitis Diseases 0.000 claims 2
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 claims 2
- 208000007903 liver failure Diseases 0.000 claims 2
- 231100000835 liver failure Toxicity 0.000 claims 2
- 230000017074 necrotic cell death Effects 0.000 claims 2
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 2
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims 2
- 208000019629 polyneuritis Diseases 0.000 claims 2
- 238000004321 preservation Methods 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 108700012359 toxins Proteins 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 201000001862 viral hepatitis Diseases 0.000 claims 2
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 208000007788 Acute Liver Failure Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 201000010000 Agranulocytosis Diseases 0.000 claims 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 1
- 206010002065 Anaemia megaloblastic Diseases 0.000 claims 1
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 206010003559 Asthma late onset Diseases 0.000 claims 1
- 206010003645 Atopy Diseases 0.000 claims 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 206010004659 Biliary cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000005623 Carcinogenesis Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 206010012441 Dermatitis bullous Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000032274 Encephalopathy Diseases 0.000 claims 1
- 208000010334 End Stage Liver Disease Diseases 0.000 claims 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 206010018687 Granulocytopenia Diseases 0.000 claims 1
- 208000003084 Graves Ophthalmopathy Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000005100 Herpetic Keratitis Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020850 Hyperthyroidism Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000002287 Keratoconus Diseases 0.000 claims 1
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 claims 1
- 208000012309 Linear IgA disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 206010027910 Mononeuritis Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 claims 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 206010036774 Proctitis Diseases 0.000 claims 1
- 206010037423 Pulmonary oedema Diseases 0.000 claims 1
- 208000006311 Pyoderma Diseases 0.000 claims 1
- 206010037779 Radiculopathy Diseases 0.000 claims 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 206010039705 Scleritis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 206010048908 Seasonal allergy Diseases 0.000 claims 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 1
- 208000009359 Sezary Syndrome Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 208000021240 acute bronchiolitis Diseases 0.000 claims 1
- 230000009798 acute exacerbation Effects 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 230000010085 airway hyperresponsiveness Effects 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 208000008445 altitude sickness Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 claims 1
- 230000036952 cancer formation Effects 0.000 claims 1
- 231100000504 carcinogenesis Toxicity 0.000 claims 1
- 239000004568 cement Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000003167 cholangitis Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 208000011444 chronic liver failure Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000428 dust Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000003912 environmental pollution Methods 0.000 claims 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 claims 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims 1
- 208000003401 eosinophilic granuloma Diseases 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 230000000925 erythroid effect Effects 0.000 claims 1
- 230000010437 erythropoiesis Effects 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 208000024711 extrinsic asthma Diseases 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 210000004195 gingiva Anatomy 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 230000002949 hemolytic effect Effects 0.000 claims 1
- 206010019692 hepatic necrosis Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 201000010884 herpes simplex virus keratitis Diseases 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 201000002597 ichthyosis vulgaris Diseases 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 230000007365 immunoregulation Effects 0.000 claims 1
- 230000004957 immunoregulator effect Effects 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 201000006334 interstitial nephritis Diseases 0.000 claims 1
- 230000003903 intestinal lesions Effects 0.000 claims 1
- 201000010659 intrinsic asthma Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 231100000149 liver necrosis Toxicity 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 210000005210 lymphoid organ Anatomy 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000008585 mastocytosis Diseases 0.000 claims 1
- 231100001016 megaloblastic anemia Toxicity 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 208000013734 mononeuritis simplex Diseases 0.000 claims 1
- 201000005518 mononeuropathy Diseases 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 238000012753 partial hepatectomy Methods 0.000 claims 1
- 230000003239 periodontal effect Effects 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 201000004338 pollen allergy Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 230000001172 regenerating effect Effects 0.000 claims 1
- 206010038718 respiratory syncytial virus bronchiolitis Diseases 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 1
- 208000004003 siderosis Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 230000007863 steatosis Effects 0.000 claims 1
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 0 **(C=C(*)C=C1)C=C1c1nc(-c2ccc(C3NCC(CC(O)=O)C3)cc2)n[o]1 Chemical compound **(C=C(*)C=C1)C=C1c1nc(-c2ccc(C3NCC(CC(O)=O)C3)cc2)n[o]1 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62131304P | 2004-10-22 | 2004-10-22 | |
| PCT/US2005/037652 WO2006047195A2 (en) | 2004-10-22 | 2005-10-18 | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008517915A JP2008517915A (ja) | 2008-05-29 |
| JP2008517915A5 true JP2008517915A5 (enExample) | 2008-11-27 |
Family
ID=36228244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007538016A Pending JP2008517915A (ja) | 2004-10-22 | 2005-10-18 | Ｓ１ｐ受容体アゴニストとしての２−（アリール）アザシクリルメチルカルボキシレート、スルホネート、ホスホネート、ホスフィネート及びヘテロ環 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7659294B2 (enExample) |
| EP (1) | EP1804793A4 (enExample) |
| JP (1) | JP2008517915A (enExample) |
| CN (1) | CN101043887A (enExample) |
| AU (1) | AU2005299851B2 (enExample) |
| CA (1) | CA2583681A1 (enExample) |
| WO (1) | WO2006047195A2 (enExample) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008509931A (ja) | 2004-08-13 | 2008-04-03 | プレーシス ファーマスーティカルズ インコーポレイテッド | スフィンゴシン−１−ホスフェート（ｓ１ｐ）レセプター活性を調節するための方法および組成物 |
| EP2003132B1 (en) | 2006-04-03 | 2014-03-05 | Astellas Pharma Inc. | Oxadiazole derivatives as S1P1 agonists |
| MY149853A (en) | 2006-09-07 | 2013-10-31 | Actelion Pharmaceuticals Ltd | Pyridin-4-yl derivatives as immunomodulating agents |
| TWI408139B (zh) | 2006-09-07 | 2013-09-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
| CL2007002594A1 (es) | 2006-09-08 | 2008-06-06 | Actelion Pharmaceuticals Ltd | Compuestos derivados de piridin-3-il, agentes inmunomoduladores; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades asociadas con un sistema inmunologico activado. . |
| CN101522646A (zh) * | 2006-09-29 | 2009-09-02 | 诺瓦提斯公司 | 具有抗炎和免疫抑制特性的二唑衍生物 |
| EP2109364A4 (en) | 2006-12-15 | 2010-04-14 | Abbott Lab | NOVEL OXADIAZONE COMPOUNDS |
| JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
| JP5390404B2 (ja) * | 2007-02-16 | 2014-01-15 | エミスフェアー・テクノロジーズ・インク | 活性薬剤を送達するための環状部分を有する化合物及び組成物 |
| DK2125797T3 (da) | 2007-03-16 | 2014-02-10 | Actelion Pharmaceuticals Ltd | Aminopyridinderivater som s1p1/edg1-receptoragonister |
| CA2684385A1 (en) | 2007-04-19 | 2008-10-30 | Glaxo Group Limited | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists |
| CN101815707B (zh) * | 2007-10-04 | 2015-09-02 | 默克雪兰诺有限公司 | 噁二唑二芳基化合物 |
| CA2700917A1 (en) | 2007-11-01 | 2009-05-07 | Actelion Pharmaceuticals Ltd | Novel pyrimidine derivatives |
| GB0722340D0 (en) * | 2007-11-14 | 2007-12-27 | Univ Leiden | Sphingosine-1-phosphate (S1P) receptor compounds |
| CA2706834A1 (en) | 2007-12-10 | 2009-06-18 | Actelion Pharmaceuticals Ltd | Thiophene derivatives as agonists of s1p1/edg1 |
| GB0725102D0 (en) * | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| GB0725101D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| GB0725105D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| PE20091339A1 (es) | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
| EP2262782B1 (en) | 2008-03-07 | 2012-07-04 | Actelion Pharmaceuticals Ltd. | Novel aminomethyl benzene derivatives |
| GB0807910D0 (en) * | 2008-04-30 | 2008-06-04 | Glaxo Group Ltd | Compounds |
| AR072184A1 (es) * | 2008-06-20 | 2010-08-11 | Glaxo Group Ltd | Derivados de oxadiazol como agonistas del receptor s1p1 |
| RU2503680C2 (ru) | 2008-07-15 | 2014-01-10 | Санофи-Авентис | ОКСАЗОЛОПИРИМИДИНЫ КАК АГОНИСТЫ РЕЦЕПТОРА Edg-1 |
| US9149459B2 (en) * | 2008-07-23 | 2015-10-06 | Novartis Ag | Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation |
| CN104311472B9 (zh) | 2008-07-23 | 2020-03-17 | 艾尼纳制药公司 | 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物 |
| US8415484B2 (en) | 2008-08-27 | 2013-04-09 | Arena Pharmaceuticals, Inc. | Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders |
| US8741923B2 (en) * | 2008-12-18 | 2014-06-03 | Merck Serono Sa | Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis |
| WO2010085582A1 (en) | 2009-01-23 | 2010-07-29 | Bristol-Myers Squibb Company | Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases |
| US8389509B2 (en) | 2009-01-23 | 2013-03-05 | Bristol-Myers Squibb Company | Substituted pyrazole compounds |
| JP2012515787A (ja) | 2009-01-23 | 2012-07-12 | ブリストル−マイヤーズ スクイブ カンパニー | 自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体 |
| CA2762137A1 (en) * | 2009-05-27 | 2010-12-02 | Leo Pharma A/S | Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof |
| US8785494B2 (en) | 2009-05-27 | 2014-07-22 | Leo-Pharma A/S | Calcium sensing receptor modulating compounds and pharmaceutical use thereof |
| GB0910674D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
| CA2767585C (en) | 2009-07-16 | 2017-09-26 | Actelion Pharmaceuticals Ltd | Pyridin-4-yl derivatives |
| US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| UY32858A (es) * | 2009-08-31 | 2011-03-31 | Abbott Healthcare Products Bv | Derivados de (tio)morfolina como moduladores de sip |
| ES2759949T3 (es) | 2009-10-29 | 2020-05-12 | Bristol Myers Squibb Co | Compuestos heterocíclicos tricíclicos |
| SG10201500639TA (en) | 2010-01-27 | 2015-03-30 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| US20130079309A1 (en) * | 2010-03-03 | 2013-03-28 | The Board Of Trustees Of The University Of Illinois | Method Of Treating Acute Lung Injury Using Sphingosine 1 Phosphate Analogs Or Sphingosine 1 Phosphate Receptor Agonists |
| EP2542554B1 (en) | 2010-03-03 | 2015-11-04 | Arena Pharmaceuticals, Inc. | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
| EP2560969B1 (en) | 2010-04-23 | 2015-08-12 | Bristol-Myers Squibb Company | 4-(5-isoxazolyl or 5-pyrrazolyl-1,2,4-oxadiazol-3-yl)-mandelic acid amides as sphingosin-1-phosphate 1 receptor agonists |
| JP5712510B2 (ja) * | 2010-06-18 | 2015-05-07 | Jnc株式会社 | ５員環を有する化合物、液晶組成物および液晶表示素子 |
| TW201643169A (zh) | 2010-07-09 | 2016-12-16 | 艾伯維股份有限公司 | 作為s1p調節劑的螺-哌啶衍生物 |
| TWI522361B (zh) | 2010-07-09 | 2016-02-21 | 艾伯維公司 | 作為s1p調節劑的稠合雜環衍生物 |
| TW201206893A (en) | 2010-07-09 | 2012-02-16 | Abbott Healthcare Products Bv | Bisaryl (thio) morpholine derivatives as S1P modulators |
| US8822510B2 (en) | 2010-07-20 | 2014-09-02 | Bristol-Myers Squibb Company | Substituted 3-phenyl-1,2,4-Oxadiazole compounds |
| ES2548258T3 (es) | 2010-09-24 | 2015-10-15 | Bristol-Myers Squibb Company | Compuestos de oxadiazol sustituidos y su uso como agonistas de S1P1 |
| ES2525298T3 (es) | 2010-11-03 | 2014-12-19 | Bristol-Myers Squibb Company | Compuestos heterocíclicos como agonistas del S1P1 para el tratamiento de enfermedades autoinmunes y vasculares |
| MX350009B (es) | 2011-01-19 | 2017-08-23 | Idorsia Pharmaceuticals Ltd | Derivados de 2-metoxi-piridin-4-ilo. |
| CN104144927B (zh) * | 2011-12-23 | 2016-08-24 | 明治制果药业株式会社 | S1p受体调节剂 |
| WO2013134562A1 (en) | 2012-03-09 | 2013-09-12 | Inception 2, Inc. | Triazolone compounds and uses thereof |
| JP6404230B2 (ja) | 2012-12-20 | 2018-10-10 | インセプション ２、 インコーポレイテッド | トリアゾロン化合物およびその使用 |
| US9115054B2 (en) | 2013-02-21 | 2015-08-25 | Bristol-Myers Squibb Company | Tetrahydronaphthalenyl compounds useful as sipi agonists |
| EA201690230A1 (ru) | 2013-09-06 | 2016-07-29 | Инсепшн 2, Инк. | Соединения триазолона и их применения |
| MA40082B1 (fr) | 2014-08-20 | 2019-09-30 | Bristol Myers Squibb Co | Nouveau compose de substitution sphingosine phosphate utile traitement maladie rhumatisme |
| ES2995737T3 (en) | 2015-01-06 | 2025-02-11 | Arena Pharm Inc | Compound for use in treating conditions related to the s1p1 receptor |
| KR102220848B1 (ko) | 2015-05-20 | 2021-02-26 | 이도르시아 파마슈티컬스 리미티드 | 화합물 (s)-3-｛4-[5-(2-시클로펜틸-6-메톡시-피리딘-4-일)-[1,2,4]옥사디아졸-3-일]-2-에틸-6-메틸-페녹시｝-프로판-1,2-디올의 결정형 |
| MA42807A (fr) | 2015-06-22 | 2018-07-25 | Arena Pharm Inc | Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1 |
| WO2017004609A1 (en) * | 2015-07-02 | 2017-01-05 | Exelixis, Inc. | Thiadiazole modulators of s1p and methods of making and using |
| JP7029445B2 (ja) | 2016-09-02 | 2022-03-03 | ブリストル－マイヤーズ スクイブ カンパニー | 置換された三環式ヘテロ環化合物 |
| CA3053416A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
| WO2018151873A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| US10993936B2 (en) | 2017-04-14 | 2021-05-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Method of treating one or more symptoms of pulmonary fibrosis by administering inhibitors of nicotinamide phosphoribotransferase |
| WO2018191747A1 (en) | 2017-04-14 | 2018-10-18 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treating pulmonary arterial hypertension |
| US11059784B2 (en) | 2017-08-09 | 2021-07-13 | Bristol-Myers Squibb Company | Oxime ether compounds |
| WO2019032632A1 (en) | 2017-08-09 | 2019-02-14 | Bristol-Myers Squibb Company | ALKYLPHENYL COMPOUNDS |
| EP3801459B1 (en) | 2018-06-06 | 2024-08-07 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
| WO2020051378A1 (en) | 2018-09-06 | 2020-03-12 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
| EP4051683A1 (en) | 2019-10-31 | 2022-09-07 | Escape Bio, Inc. | Solid forms of an s1p-receptor modulator |
| KR20220103750A (ko) * | 2019-11-20 | 2022-07-22 | 아레나 파마슈티칼스, 인크. | S1p1 수용체와 관련된 상태를 치료하는 방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1199956C (zh) * | 2000-04-21 | 2005-05-04 | 盐野义制药株式会社 | 具有抗癌作用的噁二唑衍生物 |
| WO2003061567A2 (en) * | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Selective s1p1/edg1 receptor agonists |
| AU2003276043A1 (en) * | 2002-06-17 | 2003-12-31 | Merck & Co., Inc. | 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists |
| WO2004035538A1 (en) * | 2002-10-15 | 2004-04-29 | Merck & Co., Inc. | Process for making azetidine-3-carboxylic acid |
| US7256206B2 (en) * | 2003-02-11 | 2007-08-14 | Irm Llc | Bicyclic compounds and compositions |
-
2005
- 2005-10-18 WO PCT/US2005/037652 patent/WO2006047195A2/en not_active Ceased
- 2005-10-18 CA CA002583681A patent/CA2583681A1/en not_active Abandoned
- 2005-10-18 US US11/665,046 patent/US7659294B2/en not_active Expired - Fee Related
- 2005-10-18 AU AU2005299851A patent/AU2005299851B2/en not_active Ceased
- 2005-10-18 CN CNA2005800362656A patent/CN101043887A/zh active Pending
- 2005-10-18 JP JP2007538016A patent/JP2008517915A/ja active Pending
- 2005-10-18 EP EP05812359A patent/EP1804793A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008517915A5 (enExample) | ||
| JP2007515432A5 (enExample) | ||
| JP2006511579A5 (enExample) | ||
| JP2008510762A5 (enExample) | ||
| CA2472713A1 (en) | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists | |
| JP2003507456A5 (enExample) | ||
| ES2649475T3 (es) | Derivados de piridin-4-ilo | |
| JP2011016800A5 (enExample) | ||
| ES2441845T3 (es) | Derivados de piridin-4-ilo como agonistas de S1P1/EDG1 | |
| JP5215666B2 (ja) | Ｂａｙ４３−９００６トシレートの熱力学的に安定な形態 | |
| JP5253400B2 (ja) | 免疫調節薬としてのピリジン−３−イル誘導体 | |
| JP2009532417A5 (enExample) | ||
| CN101965345B (zh) | 吡啶化合物 | |
| JPH11500731A (ja) | 免疫抑制剤活性を有する２，６−ジアリールピリダジノン | |
| JP2020523351A5 (enExample) | ||
| WO2016023877A1 (en) | Novel pyridazones and triazinones for the treatment and prophylaxis of hepatitis b virus infection | |
| CA2513081A1 (en) | Pyrrolopyridazine derivatives | |
| NO20063298L (no) | Benzensulfonylamino-pyridin-2-yl-derivater og beslektede forbindelser som inhibitorer for 11-beta-hydroksy steroid dehydrogenase type 1(11-beta-hsd-1) for behandling av diabetes og fedme | |
| CN1246119A (zh) | 吡咯并[3,4－d]－嘧啶酮衍生物及其作为药物的用途 | |
| JP2009073859A (ja) | 置換シクロペンタン誘導体の調製方法及びその新規結晶構造 | |
| JP2007530598A5 (enExample) | ||
| JP2015535832A5 (enExample) | ||
| JP2007501831A5 (enExample) | ||
| JP2007527909A5 (enExample) | ||
| JP2007532627A5 (enExample) |